Search

Your search keyword '"I Moya-Carmona"' showing total 35 results

Search Constraints

Start Over You searched for: Author "I Moya-Carmona" Remove constraint Author: "I Moya-Carmona"
35 results on '"I Moya-Carmona"'

Search Results

1. Real-life cost-effectiveness of benralizumab in patients with severe asthma

2. Real-life experience with benralizumab during 6 months

6. Real-life cost-effectiveness of benralizumab in patients with severe asthma

7. 4CPS-338 Use and efficacy of tocilizumab in patients with severe COVID-19 pneumonia

8. 5PSQ-166 Management of toxicities related to cyclin dependent kinase 4/6 inhibitors in metastatic breast cancer

9. 5PSQ-150 Disseminated intravascular coagulation after PD-1 blockade with nivolumab in advanced melanoma: a case report

10. 5PSQ-025 Pharmaceutical intervention for the optimisation of the use of antibiotics in a tertiary hospital

11. 4CPS-195 Pharmaceutical interventions in parenteral nutrition for critically ill patients

12. 4CPS-053 Antimicrobial stewardship programme in an intensive care unit

13. 4CPS-046 Monitoring the prescription of new antibiotics: the work of the antimicrobial stewardship team in a third level hospital

14. 5PSQ-027 Effectiveness and safety of tolvaptan and urea for the treatment of severe symptomatic hyponatraemia: a case series

15. 4CPS-218 Assessment of clinical pharmacist interventions in an intensive care unit

16. 5PSQ-037 Analysis of human immunodeficiency virus postexposure prophylaxis in a third-level hospital

17. 2SPD-024 Implemented strategies to solve medicines shortages

18. 1ISG-016 Evaluation of substitution and switch to etanercept biosimilar and related cost savings

19. 4CPS-159 Quality of life assessment and efficacy of secukinumab in plaque psoriasis disease

20. 1ISG-017 Analysis of prescribing quality index (pqi) in hospital care and strategies for improvement

21. 2SPD-026 Medicines’ shortage and hospital pharmacists’ strategies

22. 4CPS-160 Use of apremilast in plaque psoriasis as an alternative to biologic treatments

23. 1ISG-015 Multiple sclerosis committee: including a pharmacist as part of the multidisciplinary team

24. 6ER-002 Assessement of efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (i-pcsk9) for hypercholesterolaemia with or without statins

25. PS-044 Proactive review of hazardous medication in the outpatient unit, according to the national institute for occupational safety and health usa

26. CP-197 Protocol compliance in the treatment of hypercholesterolaemia with protein convertase SUBTILISIN-LIKE/KEXIN type 9 inhibitors (PCSK9 inhibitors)

27. GM-016 Economic impact of implementing electronic prescription of enteral nutrition and dietotherapeutic treatments

28. CP-129 Use of macitentan on pulmonary arterial hypertension as an alternative to other endotelin receptor antagonists

30. PRS9 - SWITCHING FROM SUBCUTANEOUS TREPROSTINIL TO INHALED TREPROSTINIL IN PULMONARY ARTERIAL HYPERTENSION TREATMENT AND ECONOMIC IMPACT EVALUATION

31. CPC-133 Telaprevir: Adverse Events in Clinical Practise: Abstract CPC-133 Table 1

32. Drug interactions: detection and pharmaceutical interventions in an outpatients unit

33. Effectiveness of 5-azacitidine in patients diagnosed with myelodysplastic syndrome

34. Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study.

35. Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis.

Catalog

Books, media, physical & digital resources